{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:32:36Z","timestamp":1787045556730,"version":"build-2736575974"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Factor XIII deficiency (FXIIID) is a rare bleeding disorder that may be congenital or acquired and is associated with significant morbidity, particularly in its congenital form, including intracranial hemorrhage, impaired wound healing, and adverse pregnancy outcomes. Unlike other coagulation factor deficiencies, FXIIID is not detected by routine coagulation screening tests, contributing to delayed diagnosis and underrecognition. This review provides an updated overview of the epidemiology, molecular biology, clinical manifestations, laboratory diagnosis, and management of FXIIID. Particular emphasis is placed on contemporary diagnostic strategies, including the advantages and limitations of functional, antigen, inhibitor, and genetic assays, as well as preanalytical and analytical pitfalls that may affect test interpretation. Special attention is given to acquired FXIIID, emerging diagnostic challenges, and complex clinical scenarios, including pregnancy, neonatal care, surgery, and anticoagulation. Persistent knowledge gaps, including assay standardization and limited evidence supporting current recommendations for managing special scenarios, are also highlighted. Continued international collaboration and prospective data collection are needed to improve diagnosis, refine treatment strategies, and strengthen future evidence-based guidance.<\/jats:p>","DOI":"10.3389\/fmed.2026.1895924","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:10:08Z","timestamp":1787044208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factor XIII deficiency: an updated approach to diagnosis and management"],"prefix":"10.3389","volume":"13","author":[{"given":"Rahaf Mahmoud","family":"Altahan","sequence":"first","affiliation":[{"name":"Hematology Unit, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh Second Health Cluster","place":["Riyadh, Saudi Arabia"]},{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1152\/ajplegacy.1944.142.4.581","article-title":"A study on the conversion of fibrinogen to fibrin.","volume":"142","author":"Robbins","year":"1944","journal-title":"Am J Physiology-Legacy Content."},{"key":"B2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0021-9258(18)70577-2","article-title":"Studies on the polymerization of fibrin; the role of the globulin: fibrin-stabilizing factor.","volume":"230","author":"Lorand","year":"1958","journal-title":"J Biol Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1126\/science.108.2802.280","article-title":"On the solubility of fibrin clots.","volume":"108","author":"Laki","year":"1948","journal-title":"Science."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.46989\/001c.155180","article-title":"Factor XIII deficiency: a review of biology, testing, and treatment.","volume":"8","author":"Jacobs","year":"2026","journal-title":"Clin Hematol Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4414\/smw.2007.11756","article-title":"Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterisation in 2005.","volume":"137","author":"Schroeder","year":"2007","journal-title":"Swiss Med Wkly."},{"key":"B6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/s-0043-1764471","article-title":"Novel insights into heterozygous factor XIII deficiency.","volume":"50","author":"Dorgalaleh","year":"2024","journal-title":"Semin Thromb Hemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.sdentj.2023.03.015","article-title":"Factor XIII deficiency in the Saudi population, an underestimated bleeding risk. review article and an illustrative case report with dental complications.","volume":"35","author":"Aljabry","year":"2023","journal-title":"Saudi Dent J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1055\/s-0029-1225765","article-title":"Factor XIII deficiency.","volume":"35","author":"Karimi","year":"2009","journal-title":"Semin Thromb Hemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/j.1538-7836.2011.04315.x","article-title":"Diagnosis and classification of factor XIII deficiencies.","volume":"9","author":"Kohler","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jtha.2023.09.032","article-title":"Heterozygosity in factor XIII genes and the manifestation of mild inherited factor XIII deficiency.","volume":"22","author":"Singh","year":"2024","journal-title":"J Thromb Haemost."},{"key":"B11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjh.13058","article-title":"Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors\u2019 Organization guideline on behalf of the British Committee for Standards in Haematology.","volume":"167","author":"Mumford","year":"2014","journal-title":"Br J Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1055\/s-0034-1395350","article-title":"Factor XIII deficiency in Iran: a comprehensive review of the literature.","volume":"41","author":"Dorgalaleh","year":"2015","journal-title":"Semin Thromb Hemost."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1515\/cclm-2011-0730","article-title":"Measurement of factor XIII activity in plasma.","volume":"50","author":"Katona","year":"2012","journal-title":"Clin Chem Lab Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ijlh.12756","article-title":"Factor XIII deficiency diagnosis: challenges and tools.","volume":"40","author":"Karimi","year":"2018","journal-title":"Int J Lab Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.blre.2016.08.002","article-title":"Autoimmune acquired factor XIII deficiency due to anti-factor XIII\/13 antibodies: a summary of 93 patients.","volume":"31","author":"Ichinose","year":"2017","journal-title":"Blood Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1538-7836.2010.04070.x","article-title":"Factor XIII: novel structural and functional aspects.","volume":"9","author":"Kom\u00e1romi","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0049-3848(16)30356-5","article-title":"Novel aspects of platelet factor XIII function.","volume":"141","author":"Mitchell","year":"2016","journal-title":"Thromb Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.thromres.2019.05.001","article-title":"Contribution of platelets, the coagulation and fibrinolytic systems to cutaneous wound healing.","volume":"179","author":"Opneja","year":"2019","journal-title":"Thromb Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1152\/physrev.00016.2010","article-title":"Factor XIII: a coagulation factor with multiple plasmatic and cellular functions.","volume":"91","author":"Muszbek","year":"2011","journal-title":"Physiol Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.thromres.2011.11.040","article-title":"Factor XIII, clot structure, thrombosis.","volume":"129","author":"Bagoly","year":"2012","journal-title":"Thromb Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1055\/s-0030-1248721","article-title":"Factor XIII and atherothrombotic diseases.","volume":"36","author":"Muszbek","year":"2010","journal-title":"Semin Thromb Hemost."},{"key":"B22","unstructured":"Updated Recommendations for the Diagnosis and Classification of Factor XIII Deficiencies.\n          \n          2025"},{"key":"B23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1160\/TH07-01-0034","article-title":"International registry on factor XIII deficiency: a basis formed mostly on European data.","volume":"97","author":"Ivaskevicius","year":"2007","journal-title":"Thromb Haemost."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1182\/blood.V124.21.2852.2852","article-title":"Clinical manifestations and bleeding episodes among heterozygote individuals of factor XIII deficiency, a short term prospective study.","volume":"124","author":"Naderi","year":"2014","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1111\/j.1538-7836.2012.04844.x","article-title":"Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity.","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/jth.13772","article-title":"Minimal factor XIII activity level to prevent major spontaneous bleeds.","volume":"15","author":"Menegatti","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0037-1604109","article-title":"Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders-prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency.","volume":"44","author":"Alavi","year":"2018","journal-title":"Semin Thromb Hemost."},{"key":"B29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12185-012-1064-3","article-title":"Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.","volume":"95","author":"Ichinose","year":"2012","journal-title":"Int J Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/jth.13748","article-title":"Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.","volume":"15","author":"Kerlin","year":"2017","journal-title":"J Thromb Haemost."},{"key":"B31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.15537\/1658-3175.1704","article-title":"Clinical and laboratory features of congenital factor XIII deficiency.","volume":"23","author":"Al-Sharif","year":"2002","journal-title":"Saudi Med J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/hemoncstem.hemoncstem-D-24-00034","article-title":"Acquired factor XIII deficiency in myeloid neoplasms: case series and review of literature.","volume":"17","author":"Haroon","year":"2024","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0035","DOI":"10.1097\/EA9.0000000000000035","article-title":"Acquired factor XIII deficiency: a scoping review.","volume":"2","author":"Duranteau","year":"2023","journal-title":"Eur J Anaesthesiol Intensive Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102689","DOI":"10.1016\/j.rpth.2025.102689","article-title":"Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients.","volume":"9","author":"Al Sharif","year":"2025","journal-title":"Res Pract Thromb Haemost."},{"key":"B35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1055\/a-1481-2733","article-title":"Acquired FXIII deficiency is associated with high morbidity.","volume":"122","author":"Duque","year":"2022","journal-title":"Thromb Haemost."},{"key":"B36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1055\/a-1181-0327","article-title":"Laboratory assessment of coagulation factor XIII.","volume":"40","author":"Schroeder","year":"2020","journal-title":"Hamostaseologie."},{"key":"B37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/ijlh.12633","article-title":"Detection of factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories.","volume":"39","author":"Jennings","year":"2017","journal-title":"Int J Lab Hematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1515\/cclm-2015-0547","article-title":"Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies.","volume":"54","author":"Cini","year":"2016","journal-title":"Clin Chem Lab Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/ijms22031002","article-title":"Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity.","volume":"22","author":"Leitner","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ab.2007.05.011","article-title":"highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma.","volume":"367","author":"Oertel","year":"2007","journal-title":"Anal Biochem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"10311","DOI":"10.1074\/jbc.272.15.10311","article-title":"Hydrolysis of gamma:epsilon isopeptides by cytosolic transglutaminases and by coagulation factor XIIIa.","volume":"272","author":"Parameswaran","year":"1997","journal-title":"J Biol Chem."},{"key":"B42","volume-title":"Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline.","year":"2008"},{"key":"B43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1055\/s-0036-1572326","article-title":"Diagnosis and management of congenital and acquired FXIII deficiencies.","volume":"42","author":"Muszbek","year":"2016","journal-title":"Semin Thromb Hemost."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.3324\/haematol.2018.203901","article-title":"Impaired factor XIII activation in patients with congenital afibrinogenemia.","volume":"104","author":"Bridey","year":"2019","journal-title":"Haematologica."},{"key":"B45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jim.2010.01.001","article-title":"highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears.","volume":"353","author":"Orosz","year":"2010","journal-title":"J Immunol Methods."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/j.1538-7836.2007.02684.x","article-title":"A collaborative study to establish the 1st International Standard for factor XIII plasma.","volume":"5","author":"Raut","year":"2007","journal-title":"J Thromb Haemost."},{"key":"B47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/jth.15596","article-title":"An international collaborative study to assign value for Total Factor XIII-B subunit antigen to the WHO 1st International Standard for Factor XIII Plasma, (02\/206): communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen.","volume":"20","author":"Raut","year":"2022","journal-title":"J Thromb Haemost."},{"key":"B48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/hae.12224","article-title":"Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.","volume":"20","author":"Williams","year":"2014","journal-title":"Haemophilia."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101032","DOI":"10.1016\/j.blre.2022.101032","article-title":"Genetic landscape in coagulation factor XIII associated defects - Advances in coagulation and beyond.","volume":"59","author":"Javed","year":"2023","journal-title":"Blood Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.jtha.2023.05.005","article-title":"new global fibrinolysis capacity assay for the sensitive detection of hyperfibrinolysis and hypofibrinogenemia in trauma patients.","volume":"21","author":"Rossetto","year":"2023","journal-title":"J Thromb Haemost."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12959-016-0076-2","article-title":"Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity.","volume":"14","author":"Kuiper","year":"2016","journal-title":"Thromb J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"100890","DOI":"10.1016\/j.xinn.2025.100890","article-title":"Practical guideline for major hereditary thrombophilia.","volume":"6","author":"Tang","year":"2025","journal-title":"Innovation."},{"key":"B53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/aje\/kwj179","article-title":"Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis.","volume":"164","author":"Wells","year":"2006","journal-title":"Am J Epidemiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv."},{"key":"B55","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/bjh.18239","article-title":"Thrombophilia testing: a British Society for haematology guideline.","volume":"198","author":"Arachchillage","year":"2022","journal-title":"Br J Haematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1055\/s-0038-1649787","article-title":"Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study.","volume":"74","author":"Brackmann","year":"1995","journal-title":"Thromb Haemost."},{"key":"B57","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0049-3848(13)70005-7","article-title":"Corifact\u2122\/Fibrogammin\u00a7P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study.","volume":"130","author":"Nugent","year":"2012","journal-title":"Thromb Res."},{"key":"B58","volume-title":"TRETTEN (coagulation factor XIII A-subunit, recombinant): Prescribing Information.","year":"2013"},{"key":"B59","volume-title":"NovoThirteen (catridecacog): Summary of Product Characteristics.","year":"2012"},{"key":"B60","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1055\/s-0038-1624581","article-title":"Recombinant FXIII (rFXIII-A2) prophylaxis prevents bleeding and allows for surgery in patients with congenital FXIII A-Subunit deficiency.","volume":"118","author":"Carcao","year":"2018","journal-title":"Thromb Haemost."},{"key":"B61","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2011-10-386045","article-title":"Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.","volume":"119","author":"Inbal","year":"2012","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e12628","DOI":"10.1002\/rth2.12628","article-title":"Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: real-world evidence.","volume":"6","author":"Poulsen","year":"2022","journal-title":"Res Pract Thromb Haemost."},{"key":"B63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000446813","article-title":"Safety of factor XIII concentrate: analysis of more than 20 years of pharmacovigilance data.","volume":"43","author":"Solomon","year":"2016","journal-title":"Transfus Med Hemother."},{"key":"B64","unstructured":"Fibrogammin 250\/1250 IU: Summary of Product Characteristics: Electronic Medicines Compendium (emc).\n          \n          2018"},{"key":"B65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood-2005-02-0788","article-title":"Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.","volume":"108","author":"Lovejoy","year":"2006","journal-title":"Blood."},{"key":"B66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.blre.2015.07.004","article-title":"Current concepts in the prevention of pathogen transmission via blood\/plasma-derived products for bleeding disorders.","volume":"30","author":"Di Minno","year":"2016","journal-title":"Blood Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2141.2004.04972.x","article-title":"Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.","volume":"126","author":"O\u2019Shaughnessy","year":"2004","journal-title":"Br J Haematol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.","volume":"119","author":"Bj\u00f6rkman","year":"2012","journal-title":"Blood."},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1111\/hae.70267","volume-title":"Obstetric and Gynaecologic Considerations in Inherited Bleeding Disorders.","author":"Connell","year":"2026"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1111\/hae.12259","article-title":"Congenital factor XIII deficiency in women: a systematic review of literature.","volume":"19","author":"Sharief","year":"2013","journal-title":"Haemophilia."},{"key":"B71","doi-asserted-by":"publisher","first-page":"103186","DOI":"10.1016\/j.rpth.2025.103186","article-title":"Neuraxial analgesia in pregnant individuals with bleeding disorders: a retrospective descriptive study of obstetric anesthesia practices and outcomes.","volume":"9","author":"Yi","year":"2025","journal-title":"Res Pract Thromb Haemost."},{"key":"B72","doi-asserted-by":"publisher","first-page":"8892225","DOI":"10.1155\/2020\/8892225","article-title":"Management of neuraxial analgesia in a parturient with factor XIII deficiency: a case report and proposed management algorithm.","volume":"2020","author":"Carroll","year":"2020","journal-title":"Case Rep Anesthesiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/hae.12726","article-title":"Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta-analysis of the literature.","volume":"22","author":"Davies","year":"2016","journal-title":"Haemophilia."},{"key":"B74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tmrv.2016.04.001","article-title":"Acquired factor XIII inhibitor in hospitalized and perioperative patients: a systematic review of case reports and case series.","volume":"30","author":"Tone","year":"2016","journal-title":"Transfus Med Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/hae.13603","article-title":"Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors.","volume":"24","author":"Beckman","year":"2018","journal-title":"Haemophilia."},{"key":"B76","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11239-025-03148-5","article-title":"Comparison of outcomes in autoimmune acquired factor XIII deficiency with and without underlying diseases: a systematic review.","volume":"59","author":"Song","year":"2026","journal-title":"J Thromb Thrombolysis."},{"key":"B77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000526489","article-title":"Factor XIII in the acute care setting and its relevance in obstetric bleeding.","volume":"50","author":"Duque","year":"2022","journal-title":"Transfus Med Hemother."},{"key":"B78","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jtha.2024.10.033","article-title":"Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document.","volume":"23","author":"Escobar","year":"2025","journal-title":"J Thromb Haemost."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance.","volume":"7","author":"Schutgens","year":"2023","journal-title":"Hemasphere."},{"key":"B80","doi-asserted-by":"publisher","first-page":"102371","DOI":"10.1016\/j.rpth.2024.102371","article-title":"Management of anticoagulation and factor XIII replacement in a patient with severe factor XIII deficiency and recurrent venous thromboembolic disease: case report and review of literature.","volume":"8","author":"Bounaix","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment.","volume":"125","author":"Palla","year":"2015","journal-title":"Blood."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/jth.13491","article-title":"Advances in the treatment of bleeding disorders.","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B83","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bjh.16133","article-title":"Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.","volume":"188","author":"Bouttefroy","year":"2020","journal-title":"Br J Haematol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11239-012-0818-3","article-title":"Acquired FXIII inhibitors: a systematic review.","volume":"36","author":"Franchini","year":"2013","journal-title":"J Thromb Thrombolysis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e0290571","DOI":"10.1371\/journal.pone.0290571","article-title":"Differences in coagulation-relevant parameters: comparing cryoprecipitate and a human fibrinogen concentrate.","volume":"18","author":"Stanford","year":"2023","journal-title":"PLoS One."},{"key":"B86","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.15167","article-title":"British society of haematology guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding.","volume":"181","author":"Green","year":"2018","journal-title":"Br J Haematol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1895924\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:10:10Z","timestamp":1787044210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1895924\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":86,"alternative-id":["10.3389\/fmed.2026.1895924"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1895924","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1895924"}}